Navigation Links
AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results

REDWOOD CITY, Calif., Nov. 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2012 and provided a corporate update.

Net loss for the third quarter of 2012 was $8.6 million, or $0.38 per share, compared with a net loss of $5.8 million, or $0.30 per share, for the third quarter of 2011.  During the third quarter of 2012, AcelRx recognized revenue of $166,000 resulting from reimbursement for work completed under a research grant from the U.S. Army Medical Research and Materiel Command, or USAMRMC, for development of its ARX-04 product candidate, a single dose Sufentanil NanoTab® for the treatment of moderate-to-severe acute pain. 

Research and development expenses for the third quarter totaled $6.9 million, compared with $3.9 million for the quarter ended September 30, 2011.  The increase was primarily due to expenditures associated with three ongoing Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.  General and administrative expenses were $1.4 million for the quarter ended September 30, 2012, compared with $1.9 million for the third quarter of 2011.  This decrease resulted primarily from lower intellectual property and market research expenses.

For the nine months ended September 30, 2012, AcelRx reported a net loss of $22.8 million, or $1.09 per share, compared with a net loss of $13.7 million, or $0.83 per share, for the same period in 2011.  As of September 30, 2012, AcelRx had cash, cash equivalents and investments of $23.4 million, compared to $31.9 million at June 30, 2012 and $35.8 million at December 31, 2011.

"We continue to make progress in the execution of our Phase 3 program for ARX-01.  During the third quarter, we initiated our third Phase 3 clinical trial, received four additional U.S. patents related to our sufentanil NanoTab technology and we were notified that ARX-01 was deemed sufficiently novel that we would be allowed to use the centralized filing procedure for ARX-01 in Europe," stated Richard King, president and CEO of AcelRx. "In addition, we completed treatment of the final subject in our Phase 3 clinical trial comparing ARX-01 to IV PCA with morphine.  We expect to announce top line data from this first trial later this month and results from our two other ARX-01 trials is expected in the first quarter of 2013."

Review of Third Quarter Accomplishments and Corporate Update

  • In August 2012, AcelRx initiated the third of three planned Phase 3 clinical trials for ARX-01, a double-blind, placebo-controlled efficacy and safety trial in adult patients with post-operative pain following hip or knee replacement surgery.  This study is designed to enroll approximately 400 patients and is being conducted at approximately 45 academic and community hospitals in the U.S.  The primary endpoint is the sum of the pain intensity difference to baseline, over the 48 hour study period, or SPID-48, which is the FDA standard for post-operative acute pain studies.
  • Dosing of the last patient in the Phase 3 open label, active comparator study comparing efficacy and safety of the Sufentanil NanoTab System to the commonly used IV PCA with morphine is complete, and top line data are expected in November, 2012.  Top line results from the two placebo-controlled Phase 3 clinical studies, one treating post-operative pain in patients following abdominal surgery and the other treating post-operative pain in patients following hip or knee replacement, are both expected during the first quarter of 2013.
  • During the third quarter, the U.S. Patent and Trademark Office issued four additional patents covering AcelRx's proprietary NanoTab technology.  AcelRx has now received a total of five U.S. patents underpinning its four product development programs and proprietary NanoTab technology.
  • The European Medicines Agency, or EMA, notified AcelRx that it will permit registration of the Sufentanil NanoTab PCA System via the centralized procedure.  This procedure will allow AcelRx to submit a single Marketing Authorization Application to the EMA for approval to market ARX-01 in all 27 EU member states, as well as in the 4 European Free Trade Association countries.
  • In early November 2012, AcelRx dosed the first patient in a Phase 2 study for ARX-04, its single dose sufentanil NanoTab product candidate for the management of acute pain.  The study is funded by a grant from the USAMRMC and will enroll approximately 100 patients following bunionectomy surgery, randomizing them into one of three groups to receive one of two sufentanil NanoTab dosage amounts (20 mcg and 30 mcg) or placebo.
  • Financial Outlook
    AcelRx anticipates that research and development expenses for the fourth quarter of 2012 and the first half of 2013 will increase as AcelRx conducts and completes the Phase 3 clinical trials for ARX-01.  Development of ARX-04 through Phase 2 clinical work and Phase 3 preparatory work is expected to be fully funded by a grant from USAMRMC.  The development of ARX-04 beyond Phase 2 and initial preparations for Phase 3 is dependent on the identification of additional funding from USAMRMC or other sources.  Additionally, AcelRx anticipates modest increases in general and administrative expenses due to costs associated with expansion of its corporate infrastructure to support ongoing development of its product candidates.

    Conference Call
    AcelRx will conduct a conference call and webcast today, November 6, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results and program updates. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers, or (412) 858-4600 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's website at A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor Relations section of the company's website at

    About AcelRx Pharmaceuticals, Inc.
    AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, is currently in Phase 3 clinical development and is designed to solve problems associated with post-operative intravenous patient-controlled analgesia, including side effects of morphine, invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates that have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.  AcelRx has initiated a Phase 2 study for a fourth product candidate, ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from the USAMRMC.
    For additional information about AcelRx's clinical programs please visit

    Forward Looking Statements
    This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' financial viability, anticipated increases in research and development and general and administrative expenses, the sufficiency of funds to support its clinical trials and operations, timing of interim and final results of its clinical trials, planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the release ARX-01 top-line clinical trial data, the release and anticipated timing of additional ARX-01 clinical trial data, the anticipated timing for remaining clinical trials, and the therapeutic and commercial potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: AcelRx ability to raise additional funds to support its clinical trials and operations; the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials, including timing, release and implications of interim or final results of the ARX-01 Phase 3 clinical trials;  the uncertain clinical development process, including the risk that planned clinical trials may not have an effective design, enroll a sufficient number of patients, or be completed on schedule, if at all; any delays or inability to obtain, regulatory approval of its product candidates; its ability to obtain adequate clinical supplies of the drug and device components of its product candidates; its ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; sufficiency of its intellectual property portfolio; the accuracy of AcelRx Pharmaceuticals' estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the three months ended September 30, 2012.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

     SELECTED FINANCIAL DATA(in thousands, except per share data)(unaudited) Three Months Ended Nine Months Ended September 30,  September 30, 2012201120122011Statement of Comprehensive Loss DataResearch grant revenue

    448Operating expenses:Research and development (1)

    6,9483,94717,1138,922General and administrative (1)

    1,4101,8665,2905,086Total operating expenses

    8,3585,81322,40314,008Loss from operations

    (8,192)(5,405)(21,684)(13,560)Interest expense

    (573)(377)(1,765)(1,891)Interest income and Other income (expense), net

    183216081,722Net loss

    (5,761)$(22,841)$(13,729)Basic and diluted net loss per common share

    (0.83)Shares used in computing basic and diluted net loss per common share

    Includes the following non-cash, stock-based compensation expense:Research and development

    578General and administrative

    304304871768Total non-cash, stock-based expense

    ,346Selected Balance Sheet DataSeptember 30, 2012December 31, 2011Cash, cash equivalents and investments

    35,785Total assets

    28,15140,835Total liabilities

    28,47823,367Total stockholders' equity (deficit)




    SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
    2. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
    3. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
    4. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
    5. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
    6. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
    7. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
    8. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
    9. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
    10. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
    11. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at
    Post Your Comments:
    (Date:10/9/2015)... REDWOOD CITY, Calif. , Oct. 9, 2015 ... a presentation will be made at the annual European Society ... th to October 14 th , 2015 at the ...  The annual EuSEM is the largest meeting of emergency medicine ... and 90 countries represented. Data from the previously ...
    (Date:10/9/2015)... Oct. 9, 2015 Ansun BioPharma announced a ... of America ) regarding the compassionate use of DAS181 ... a respirator who was co-infected with influenza and parainfluenza ... of therapy, O 2 requirement was reduced and ... able to go off the respirator on day 5. ...
    (Date:10/9/2015)... , Schweiz, October 9, 2015 Der ... Dr.   Yutaka Kondo und Dr.   Junko Takita ...   2015 " geht an Dr.   Yutaka ... Der " JCA-Mauvernay Award   2015 ... Dr.   Junko Takita    ™ , das ...
    Breaking Medicine Technology:
    ... Nov. 9, 2011 BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX® in the U.S. ... Tom Wegman, will present at the upcoming Lazard Capital ... Wednesday, November 16, 2011 in New York, NY.   ...
    ... 9, 2011 NeuroDerm , Ltd. ... and pharmacokinetic trial of ND0611, administered as an adjunct ... or Stalevo ® , in patients with advanced Parkinson,s ... sub-cutaneously via a dermal patch to increase the bioavailability ...
    Cached Medicine Technology:
    (Date:10/10/2015)... York, NY (PRWEB) , ... October 10, 2015 , ... ... some alarming numbers on the growth of cybercrime costs for US companies. The New ... on Tuesday, October 6th. With averages showing increases hovering around 20% among the companies ...
    (Date:10/10/2015)... , ... October 10, 2015 , ... Isabel Healthcare will ... , On the heels of the release of the Institute of Medicine’s latest report ... their integration with Cerner solutions that assist healthcare providers and consumers to potentially reduce ...
    (Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic ... for Graduate Medical Education J. Michael Finley, DO, as the recipient of the ... for his impact on graduate medical education opportunities for osteopathic residents, and his ...
    (Date:10/9/2015)... ... 2015 , ... A new health tool that helps identify if a sore ... ) – just in time for the cold and flu season, which the ... many in the U.S., the real start of cold/flu season is the start of ...
    (Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington ... orthodontic system that uses clear, plastic aligners. This alternative to braces has become ... which allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, ...
    Breaking Medicine News(10 mins):
    ... serious problem that can often be fatal. Methadone has ... addicts. However, the major concern in treating heroin addicts ... is one reason methadone therapy is usually only given ... that an alternative drug therapy combined with psychosocial treatment ...
    ... researchers are currently testing the safety of hypothermia ... injury. Hypothermia treatment has been shown to be ... but its effectiveness in treating children with traumatic ... decreases inflammation, excitotoxicity (excessive neurotransmitters released with injury ...
    ... of skin cancer and it has been shown through previous ... sunlight, whose UV rays cause damage to DNA that triggers ... are more prone than others to melanoma. Researchers have now ... people with melanoma that those with fair skin// have lowered ...
    ... Affective Disorder(SAD) is not all that well understood, but ... sunlight in the winter months. Winter depression involves suffering ... days get longer and nights get shorter. Other SAD ... sleeping for longer than usual. Researchers have now found ...
    ... hospital in Kolkatta, India recently received a patient, a two-month-old ... suffering from a rare disease caused due to a deficiency ... of 10 million children. Doctors said that the baby was ... On detection the baby, a boy child, was found to ...
    ... time to its ultraviolet rays, has always been said to be ... shown that even moderate sun exposure can result in moles that ... to sun has been shown as the main risk factor for ... rarest type of skin cancer, is much weaker. It has however, ...
    Cached Medicine News:
    The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
    For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
    Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
    Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
    Medicine Products: